ibd and glp 1 Relevance of Glucagon-Like Peptide (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review A schematic representation of the

Improved energy and reduced cravings can also be a positive sign that the medication is starting to work

Results take time-usually weeks of consistent use

These injectable medications enhance a gut hormone that signals fullness, thereby aiding weight loss

High costs and restrictive insurance coverage may present market challenges

However: Larger meta-analyses show no significant increase in risk after adjusting for confounders [25] Incidence appears similar to other diabetes therapies [25] Much of the observed signal likely reflects: Baseline risk (obesity, T2DM) Secondary gallstone disease In summary, pancreatitis in GLP-1 users is a rare and possible complication, but current evidence does not support a substantial increase in risk directly related to GLP-1 agents